Pharma company lawsuit forces Dutch health agency to reassess cancer drug


9 July 2024 - The Dutch healthcare procurement agency has said it will reassess the breast cancer drug abemaciclib after being ordered to do so by the court of Amsterdam, in a case brought by pharmaceutical company Eli Lilly.

The Dutch National Health Care Institute (Zorginstituut Nederland) decides which new drugs should be funded through the healthcare system, in a similar way to NICE for the NHS in England and Wales.

The lawsuit was filed in response to the institute’s recommendation to the Dutch health minister not to reimburse the cost of Eli Lilly’s drug abemaciclib (Verzenio) for adults with a certain type of early stage breast cancer.

Read BMJ article 

Michael Wonder

Posted by:

Michael Wonder